| Extended-duration dosing and distribution of dalbavancin into bone and articular tissue MW Dunne, S Puttagunta, CR Sprenger, C Rubino, S Van Wart, ... Antimicrobial agents and chemotherapy 59 (4), 1849-1855, 2015 | 207 | 2015 |
| Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis GE Thwaites, SM Bhavnani, TTH Chau, JP Hammel, ME Török, ... Antimicrobial agents and chemotherapy 55 (7), 3244-3253, 2011 | 170 | 2011 |
| Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections AK Meagher, JA Passarell, BB Cirincione, SA Van Wart, K Liolios, ... Antimicrobial agents and chemotherapy 51 (6), 1939-1945, 2007 | 129 | 2007 |
| Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections JA Passarell, AK Meagher, K Liolios, BB Cirincione, SA Van Wart, ... Antimicrobial agents and chemotherapy 52 (1), 204-210, 2008 | 125 | 2008 |
| Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia D Andes, PG Ambrose, JP Hammel, SA Van Wart, V Iyer, DK Reynolds, ... Antimicrobial agents and chemotherapy 55 (5), 2113-2121, 2011 | 122 | 2011 |
| Pharmacokinetics and leukocyte responses of recombinant human interleukin-10 E Radwanski, A Chakraborty, S Van Wart, RD Huhn, DL Cutler, ... Pharmaceutical research 15, 1895-1901, 1998 | 90 | 1998 |
| Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia CM Rubino, SA Van Wart, SM Bhavnani, PG Ambrose, JS McCollam, ... Antimicrobial agents and chemotherapy 53 (10), 4422-4428, 2009 | 84 | 2009 |
| Pharmacokinetic–pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients SA Van Wart, DR Andes, PG Ambrose, SM Bhavnani Diagnostic microbiology and infectious disease 63 (4), 409-414, 2009 | 77 | 2009 |
| Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections SA Van Wart, JS Owen, EA Ludwig, AK Meagher, JM Korth-Bradley, ... Antimicrobial agents and chemotherapy 50 (11), 3701-3707, 2006 | 75 | 2006 |
| Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections S Van Wart, L Phillips, EA Ludwig, R Russo, DA Gajjar, A Bello, ... Antimicrobial agents and chemotherapy 48 (12), 4766-4777, 2004 | 67 | 2004 |
| Defining clinical exposures of cefepime for Gram-negative bloodstream infections that are associated with improved survival NJ Rhodes, JL Kuti, DP Nicolau, S Van Wart, AM Nicasio, J Liu, BJ Lee, ... Antimicrobial agents and chemotherapy 60 (3), 1401-1410, 2016 | 60 | 2016 |
| Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis PG Ambrose, JB Anon, JS Owen, S Van Wart, ME McPhee, SM Bhavnani, ... Clinical infectious diseases 38 (11), 1513-1520, 2004 | 42 | 2004 |
| Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus … SA Van Wart, PG Ambrose, CM Rubino, T Khariton, TA Riccobene, ... Antimicrobial agents and chemotherapy 58 (2), 885-891, 2014 | 36 | 2014 |
| Population pharmacokinetics of tigecycline in healthy volunteers SA Van Wart, BB Cirincione, EA Ludwig, AK Meagher, JM Korth‐Bradley, ... The Journal of Clinical Pharmacology 47 (6), 727-737, 2007 | 35 | 2007 |
| Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes JT Schiffer, DA Swan, A Magaret, L Corey, A Wald, J Ossig, ... Science translational medicine 8 (324), 324ra15-324ra15, 2016 | 34 | 2016 |
| Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community‐acquired bacterial pneumonia SA Van Wart, A Forrest, T Khariton, CM Rubino, SM Bhavnani, ... The Journal of Clinical Pharmacology 53 (11), 1155-1167, 2013 | 34 | 2013 |
| Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization DR Andes, DK Reynolds, SA Van Wart, AJ Lepak, LL Kovanda, ... Antimicrobial agents and chemotherapy 57 (11), 5714-5716, 2013 | 33 | 2013 |
| Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study N Carrillo, MC Malicdan, P Leoyklang, JA Shrader, G Joe, C Slota, ... Genetics in medicine 23 (11), 2067-2075, 2021 | 32 | 2021 |
| Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies CR Rayner, CC Bulik, MA Kamal, DK Reynolds, S Toovey, JP Hammel, ... Antimicrobial agents and chemotherapy 57 (8), 3478-3487, 2013 | 29 | 2013 |
| Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints PG Ambrose, AK Meagher, JA Passarell, SA Van Wart, BB Cirincione, ... Diagnostic microbiology and infectious disease 63 (1), 38-42, 2009 | 25 | 2009 |
